Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Liabilities and Shareholders Equity (2020 - 2025)

Journey Medical (DERM) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $85.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 33.02% year-over-year to $85.2 million, compared with a TTM value of $331.6 million through Sep 2025, up 21.6%, and an annual FY2024 reading of $80.2 million, up 4.41% over the prior year.
  • Liabilities and Shareholders Equity was $85.2 million for Q3 2025 at Journey Medical, up from $81.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $120.9 million in Q1 2022 and bottomed at $64.0 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $86.5 million, with a median of $85.0 million recorded in 2025.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 87.42% in 2021, then plummeted 39.05% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $97.3 million in 2021, then increased by 8.1% to $105.2 million in 2022, then decreased by 26.92% to $76.8 million in 2023, then grew by 4.41% to $80.2 million in 2024, then grew by 6.17% to $85.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for DERM at $85.2 million in Q3 2025, $81.2 million in Q2 2025, and $85.0 million in Q1 2025.